Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Clinton déjà vu

    Curbed enthusiasm Clinton déjà vu The market reaction to Hillary Clinton's Sept. 21, 2015, tweet about drug pricing was strikingly similar to what happened when she tackled the same issue more than two decades ago…

    Published on 1/4/2016
  • Figure: M&A activity

    Curbed enthusiasm M&A activity The aggregate transaction value for M&A deals completed in 2015 was $168 billion. The figure was far and away the largest amount seen for the industry over the past 16 years, but it …

    Published on 1/4/2016
  • Figure: Raised by market cap

    Curbed enthusiasm Raised by market cap Money raised by public companies more than doubled to $97.4 billion in 2015 vs. $45.7 billion in 2014. In 2015, there were 494 companies that tapped the markets vs. 475 …

    Published on 1/4/2016
  • Table: Follow-on performance

    Curbed enthusiasm Follow-on performance Although the volume of follow-ons steadily declined throughout 2015 — dipping to 24 deals in 4Q from 46 in 3Q, 60 in 2Q and 94 in 1Q — last year saw companies raise a total …

    Published on 1/4/2016
  • Table: IPO performance

    Curbed enthusiasm IPO performance In 4Q, 19 companies raised $1.2 billion in IPOs. For the full year, 83 companies raised $8 billion, which was the third largest annual amount raised since 1994, when BioCentury …

    Published on 1/4/2016
  • Curbed enthusiasm

    Why tempered investor enthusiasm doesn't mean the biotech bull is over

    Nobody is calling an end to the biotech bull, but expectations for the sector are not overflowing with optimism.

    Published on 1/4/2016
  • Trans-Pacific dreams

    How TPP deal's IP provisions read like a wish list from PhRMA, biologics aside

    Drug companies lost on biologics exclusivity in TPP but won big time on other IP provisions.

    Published on 12/21/2015
  • Table: Biopharma-friendly TPP provisions

    Trans-Pacific dreams Biopharma-friendly TPP provisions The Trans-Pacific Partnership includes IP and other provisions that favor biopharmaceutical innovators. The IP protections resemble those provided in the U.S.…

    Published on 12/21/2015
  • Box: Building CoMMpass

    Following CoMMpass Building CoMMpass The Multiple Myeloma Research Foundation conceived of the CoMMpass study in 2009 to capitalize on insights into the molecular profile of multiple myeloma gleaned from the …

    Published on 12/14/2015
  • Table: Highlighting CoMMpass

    Following CoMMpass Highlighting CoMMpass Results from the CoMMpass study presented at this month's American Society of Hematology meeting included seven abstracts and analyses derived from over 700 multiple …

    Published on 12/14/2015
  • Table: Initiating mutations

    Following CoMMpass Initiating mutations Data from the CoMMpass study presented at this month's American Society of Hematology meeting identified 18 disease-initiating mutations in newly diagnosed multiple myeloma …

    Published on 12/14/2015
  • Following CoMMpass

    How a patient-run study is influencing R&D and treatment in myeloma

    A massive clinical study in MM that was conceived of and is led by patients is influencing what drugs are developed and will determine how they are used.

    Published on 12/14/2015
  • Figure: Kyndrisa efficacy trials

    Talking the walk Kyndrisa efficacy trials The NDA for Kyndrisa drisapersen from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) included three placebo-controlled studies to treat Duchenne muscular dystrophy, with six-…

    Published on 12/7/2015
  • Talking the walk

    Why eteplirsen's smaller DMD data set may be more robust than Kyndrisa's

    FDA has hinted at a modest efficacy threshold in DMD, suggesting Sarepta's smaller data set could prove more robust than BioMarin's.

    Published on 12/7/2015
  • More with less

    How Merck KGaA's new R&D chief is shaping the pipeline

    The first half of next year will bring evidence of whether Merck Serono's new R&D chief has put the pipeline on solid footing.

    Published on 11/23/2015
  • Figure: Merck KGaA's pipeline progress

    More with less Merck KGaA's pipeline progress In his first 16 months as head of R&D at Merck KGaA (Xetra:MRK)'s biopharma unit, Luciano Rossetti has advanced six programs within the company's core focus areas of …

    Published on 11/23/2015
  • Scaling compassion

    FDA, industry, patient groups charting compassionate use policies

    Compassionate use experiments are improving fairness and transparency but are not sufficient to ensure access or avert aggressive social media campaigns.

    Published on 11/16/2015
  • Demanding rights

    State right-to-try laws reveal patient demand for preapproval access to drugs

    The most controversial preapproval access experiment is being conducted by state legislatures. Critics say right-to-try laws help no one.

    Published on 11/16/2015
  • Pfizer's growth spurt

    How Allergan would fit with Pfizer

    Pfizer has created its own growth story over the last 18 months, making a takeout of Allergan more an amenity than a necessity.

    Published on 11/9/2015
  • Box: Establishing the business

    Pfizer's growth spurt Establishing the business Pfizer Inc.'s established pharma business includes drugs that are generic or will be by the end of 2015, as well as biosimilars and sterile injectables. Revenues …

    Published on 11/9/2015
  • Figure: Growth potential

    Pfizer's growth spurt Growth potential Since last year’s aborted attempt to acquire AstraZeneca plc (LSE:AZN; NYSE:AZN), Pfizer Inc. (NYSE:PFE) has increased top- and bottom-line growth rates through acquisition …

    Published on 11/9/2015
  • Figure: Pfizer's pipeline progress

    Pfizer's growth spurt Pfizer’s pipeline progress In the last 18 months, Pfizer Inc. (NYSE:PFE) has gotten three new products approved and advanced 10 other late-stage programs to the next phase of development or …

    Published on 11/9/2015
  • Figure: Trailing off?

    Flight to liquidity Trailing off? Private investing by some of biotech's most active crossover investors, such as Fidelity, Rock Springs and Jennison, appears to be dropping off this quarter, but with two months …

    Published on 11/2/2015
  • Table: Crossing guards

    Flight to liquidity Crossing guards The 27 IPOs shown below — which constitute three-quarters of the 36 U.S. IPOs that raised more than $100 million in 2014-15 — all received crossover funds while still private. …

    Published on 11/2/2015
  • Flight to liquidity

    How crossover fall-off is changing private financing strategies

    An uncertain IPO market is eliminating an arbitrage opportunity that helped fuel the sector's biggest and most successful public exits.

    Published on 11/2/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993